KM Research Hub
DIGITIZATION RESULTS

KM 曲线提取结果

共 243 篇,按论文发表时间从新到旧排列。

论文发表日期KM Figure面板成功提取曲线数状态
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.PMID 39756844 · Lancet Haematol 2025-Jan 1111 质量警告
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.PMID 39854658 · JCO Precis Oncol 2025-Jan 1223 质量警告
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.PMID 39970442 · CA Cancer J Clin 2025 1444 质量警告
Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.PMID 41194933 · Front Immunol 2025 2213 部分完成
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.PMID 39316666 · Blood 2024-Dec-26 1333 质量警告
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.PMID 39715755 · Signal Transduct Target Ther 2024-Dec-24 35521 质量警告
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.PMID 39279580 · J Clin Oncol 2024-Dec-20 3448 提取完成
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.PMID 39361946 · J Clin Oncol 2024-Dec-20 1113 质量警告
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.PMID 39690158 · Signal Transduct Target Ther 2024-Dec-18 1336 提取完成
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.PMID 39475359 · Clin Cancer Res 2024-Dec-02 3121224 提取完成
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.PMID 39480453 · JAMA Oncol 2024-Dec-01 1224 提取完成
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.PMID 39173098 · J Clin Oncol 2024-Dec 4111121 质量警告
First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.PMID 39382718 · Int J Clin Oncol 2024-Dec 2448 提取完成
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.PMID 39631145 · EBioMedicine 2024-Dec 3121221 质量警告
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.PMID 39609425 · Blood Cancer J 2024-Nov-28 37720 提取完成
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.PMID 39608979 · J Immunother Cancer 2024-Nov-27 26610 提取完成
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.PMID 39532849 · Signal Transduct Target Ther 2024-Nov-13 16612 提取完成
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.PMID 39102624 · J Clin Oncol 2024-Nov 24412 提取完成
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.PMID 39162872 · Gastric Cancer 2024-Nov 3444 质量警告
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.PMID 39177931 · Breast Cancer Res Treat 2024-Nov 1224 提取完成
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.PMID 39237634 · Leukemia 2024-Nov 2335 质量警告
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.PMID 39284381 · Ann Oncol 2024-Nov 26612 提取完成
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.PMID 39313594 · Nat Med 2024-Nov 5111130 质量警告
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].PMID 39418883 · ESMO Open 2024-Nov 1223 质量警告
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.PMID 39082668 · Blood 2024-Oct-31 26615 质量警告
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).PMID 39519198 · Int J Mol Sci 2024-Oct-30 1223 提取完成
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.PMID 39455094 · J Immunother Cancer 2024-Oct-24 28810 质量警告
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.PMID 39442958 · BMJ 2024-Oct-23 1336 提取完成
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.PMID 38968156 · Blood Adv 2024-Oct-22 38811 质量警告
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.PMID 39413375 · N Engl J Med 2024-Oct-17 1224 提取完成